Acetylcholinesterase inhibitors (AChEIs) are pivotal in managing Alzheimer's disease and other dementias by impeding the enzyme acetylcholinesterase. This enzyme normally degrades acetylcholine, a neurotransmitter crucial for cognitive functions like memory and learning. In Alzheimer's, a deficit of acetylcholine arises from the loss of cholinergic neurons. AChEIs help sustain higher acetylcholine levels in the brain, offering temporary relief from cognitive symptoms such as memory loss and confusion. While they do not halt or reverse disease progression, these medications can significantly enhance quality of life. Common AChEIs include donepezil, rivastigmine, and galantamine, each with potential side effects like nausea and insomnia. Effective management requires ongoing monitoring and adjustments by healthcare providers to optimize therapeutic benefits.
Jun Hua
Johns Hopkins University , United States
Nazneen N Dewji
Cenna Biosciences Inc, United States
Jacqueline London
Paris Diderot University, FranceSubmit your abstract Today
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Make a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Health care professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Somali Red Crescent Society, Somalia
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States